Status:
COMPLETED
Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
Lead Sponsor:
Leiden University Medical Center
Collaborating Sponsors:
Sanquin Research & Blood Bank Divisions
Landsteiner Foundation for Blood Transfusion
Conditions:
Fetal and Neonatal Alloimmune Thrombocytopenia
Eligibility:
FEMALE
Brief Summary
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is the most common cause of severe thrombocytopenia in otherwise healthy born neonates. FNAIT results in a risk of bleeding the most severe compl...
Detailed Description
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is the most common cause of severe thrombocytopenia in neonates. It is an immunological process, in which Human Platelet Antigen (HPA) alloantibo...
Eligibility Criteria
Inclusion
- All pregnant women, of whom routine blood samples are taken at 27 weeks gestational age (GA).
Exclusion
- There are no predefined exclusion criteria, since we are aiming to determine the incidence in the complete pregnant population in the Netherlands.
- \[ WILSONBEKWAAM EXCLUSIE\]
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
3660 Patients enrolled
Trial Details
Trial ID
NCT04067375
Start Date
March 1 2017
End Date
April 1 2020
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stichting Bloedbank Sanquin
Amsterdam, Netherlands, 1066 CX